Insect Cell Culture Media Patents: Top Companies & Trends 2026
- 28.1% concentration at the top. The five leading assignees hold 852 of 3,032 records in scope, but that still leaves a long tail of single- and few-filing entrants below tenth place.
- Filing has cooled from its 2021 peak. Filings ran from 88 in 2021 to 42 in 2024, a -52% move over that span, though the two most recent years are still filling in due to publication lag.
- Almost every record touches C12N. 93.2% of the 3,032 records carry a C12N classification, with C07K and A61K close behind — the field reads as a genetic-engineering and protein-production story more than a media-formulation-only one.
Filing growth compares 2021 (88 records) with 2024 (42) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 3,032 records in scope (CR5), not by the ranked leaders only.
What this patent set covers
This landscape covers patent families and published applications combining insect cell or baculovirus culture systems with media formulation elements — amino acid supplementation, growth factors, lipid supplements, glucose and osmolality control, and serum replacement — filed against IPC classes C12N5/06, C12N7/00 and C12M3/00. The scope runs from 2015 through the 2026-07-31 data cut-off, giving 3,032 records across which patent family counting was used for the assignee ranking so that continuation filings and multi-jurisdiction duplicates do not inflate any single applicant’s position.
The dataset sits at the intersection of two older, larger disciplines: recombinant protein expression via baculovirus/insect systems, and cell culture media engineering. Because most records also carry classifications for peptides, proteins and medicinal preparations, the media-formulation claims are frequently embedded inside broader biologics production or vaccine manufacturing filings rather than standing alone.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 3,032 records: how filing activity has moved year over year, and which IPC subclasses the claims actually sit in.
Filing trend, 2017–2026
Annual filings rose to a peak of 88 in 2021 before declining to 42 by 2024, a -52% move over that three-year span. 2025 and 2026 counts are still climbing as publications catch up to filing dates roughly 18 months behind, so the apparent recent drop should not be read as the field slowing down yet.
IPC subclass composition
C12N (microorganisms and genetic engineering) appears on 93.2% of the 3,032 records, with C07K (peptides and proteins) on 73.4% and A61K (medicinal preparations) on 71.6%. Because records can carry multiple classes, these percentages sum to well over 100% — the pattern shows a field built around expression-and-production claims that happen to specify media conditions, rather than pure formulation chemistry.
Shares are the percentage of the 3,032 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Insect Cell Culture Media Formulation with Eureka
This page is one run against one query. Ask Eureka your own question about insect cell culture media formulation and every answer comes back with the patent numbers behind it.
Try EurekaRepresentative filing and most-cited records
Sparged insect cell culture and the expression of recombinant proteins therein (WO1991000341A1)
Methods of growing insect cells in sparged culture, particularly in airlift fermentors, to high cell densities with high viability. The filing discloses media comprising a non-toxic protective agent, typically a water-soluble polymer, plus operating parameters such as sparging rates and bubble sizes chosen to minimise cell damage during large-scale culture for recombinant protein and virus production.Filed by Cetus Corporation, dated 1991-01-10 — one of the earliest documents in this space and a reference point for later sparging and shear-protection claims.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20040093621A1 | Antibody composition which specifically binds to CD20 | 3,538 |
| 2 | US20030115614A1 | Antibody composition-producing cell | 3,303 |
| 3 | US20040132140A1 | Production process for antibody composition | 2,989 |
| 4 | US20040110282A1 | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost | 2,865 |
| 5 | US6352694B1 | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands … | 2,318 |
| 6 | US6534055B1 | Methods for selectively stimulating proliferation of T cells | 2,048 |
| 7 | US6887466B2 | Methods for selectively stimulating proliferation of T cells | 2,030 |
| 8 | US6905681B1 | Methods for selectively stimulating proliferation of T cells | 2,018 |
| 9 | US6905680B2 | Methods of treating HIV infected subjects | 1,820 |
| 10 | US4745051A | Method for producing a recombinant baculovirus expression vector | 1,049 |
Citation counts favour older filings simply because they have had more years to accumulate citations within this corpus — treat them as a signal of influence on later filers, not as a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers say
Read alongside the assignee ranking and filing trend, three patterns stand out for anyone deciding where to file next.
A moderate lead, not a monopoly
The leading assignee holds 516 records and the top five combine for 852, or 28.1% of the 3,032 records in scope. Tenth place sits at 58, meaning the drop-off from leader to mid-table is steep but the ranked group still spans a wide range of filing volumes rather than a single dominant player.
Down from a 2021 peak, reading pending
Filings peaked at 88 in 2021 and had fallen to 42 by 2024, a -52% move over that span. Because publication lags filing by roughly 18 months, 2025 and 2026 figures are undercounted and should not be read as confirming a continued decline.
Genetic engineering claims dominate
C12N appears on 93.2% of records, C07K on 73.4%, and A61K on 71.6%. G01N (material analysis, 29.4%) and C07H (sugars and nucleic acids, 19.3%) sit much further down, suggesting formulation-specific analytical and carbohydrate-control claims are comparatively less crowded.
A small, tight inventor cluster
Only 10 co-assignee pairs appear in the data, with the strongest pairing filing together 95 times. This points to a handful of tightly linked inventor groups rather than a broad web of cross-company collaboration across the field.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to insect cell culture media formulation, with the prior art for and against each one.
Who is filing, and where the gaps sit
The ranked leaders include large biologics and vaccine houses alongside university and government research bodies — a mix that reflects the field's roots in recombinant protein and virus-like-particle production.
A clear single leader
The top-ranked assignee holds 516 records, well ahead of second place, reflecting sustained filing around baculovirus-based recombinant protein production over the covered period.
A steep but populated mid-table
Volume falls from 516 at the top to 70 at fifth place and 58 at tenth, then continues into a long tail across the remaining ranked companies — plenty of room for a well-targeted filer to reach the mid-table without displacing the leader.
Filing is largely solo
With only 10 identified co-assignee pairs across the corpus, most filings name a single corporate or institutional assignee rather than a joint venture or multi-party collaboration.
| Assignee | Recent year | YoY |
|---|---|---|
| Human Genome Sciences, Inc. | 0 | — |
| RUBEN STEVEN M | 0 | — |
| Medicago Inc. | 0 | — |
| ROSEN CRAIG A | 0 | — |
| Immunex Corp. | 0 | — |
| Regents of the University of California | 0 | — |
| Iowa State University Research Foundation, Inc. | 0 | — |
| NI JIAN | 0 | — |
Where to take this analysis
The dataset points to specific next steps depending on whether the goal is freedom-to-operate, competitive tracking, or identifying a filing gap.
Check freedom to operate against the leader
With one assignee holding 516 records, any new filing in baculovirus expression media should be checked against that portfolio's claim scope before development spend commits to a specific formulation route.
Run a claim-scope check in Eureka →Watch the under-claimed branches
Osmolality control, glucose-feed strategies and serum-free lipid supplementation show lower relative filing density than the core genetic-engineering classes — a starting point for a first-claim search.
Explore white space in Eureka →Track momentum, not just rank
Recent-year filing counts by assignee move faster than cumulative totals and flag which players are still actively building portfolios versus holding legacy positions.
Monitor assignee activity in Eureka →Common questions
The dataset ranks 100 assignees by patent family count, with the leading company holding 516 of the 3,032 records in scope. The top five combined hold 852 records, or 28.1% of the total, which is a meaningful concentration but far from a monopoly — the remaining 71.9% is spread across the other 95 ranked companies plus unranked filers. Anyone assessing competitive risk should look at both the leader's portfolio and the mid-table cluster around fifth to tenth place, since volumes there (70 and 58 records respectively) are still substantial.
Filings peaked at 88 in 2021 and fell to 42 by 2024, a -52% move over that three-year span, which is the most recent period that can be treated as complete. Because patent publication typically lags actual filing by around 18 months, the 2025 and 2026 figures in any chart are still incomplete and will rise as more applications publish. The honest read is a cooling from a 2021 high, not a confirmed downward trend into the present.
It means nearly all records in this scope are classified under microorganisms and genetic engineering (C12N), not that the field is purely about that subject — records commonly carry several IPC classes at once, which is why C12N, C07K (73.4%) and A61K (71.6%) all appear on large, overlapping shares of the same 3,032 records. In practice this tells you that insect cell media formulation claims are usually embedded inside broader recombinant protein or biologics production filings rather than filed as standalone media patents.
WO1991000341A1, filed by Cetus Corporation in 1991, discloses sparged insect cell culture methods using airlift fermentors together with media containing a non-toxic protective polymer and specific sparging parameters to limit shear damage. As an early-1990s filing its original term has long since expired, so it no longer blocks new filings directly, but it remains a key prior-art reference that later shear-protection and large-scale sparging claims are commonly compared against. Anyone filing a new claim around bubble-size control or protective-agent media should expect examiners to cite it or its descendants.
Relative to the dominant C12N genetic-engineering claims, subclasses like G01N (material analysis and testing, 29.4% of records), C12Q (enzyme/DNA measuring, 25.8%) and C07H (sugars and nucleic acids, 19.3%) carry noticeably lower filing density. That pattern suggests narrower, more specific formulation and monitoring claims — osmolality control, glucose-feed strategies, and serum-free lipid supplement blends among them — are comparatively less crowded than the broad expression and production claims that dominate the corpus. A first-claim search in those narrower branches is a reasonable starting point before committing to a filing strategy.
Research Insect Cell Culture Media Formulation in depth with Eureka
Go past this page: query the whole insect cell culture media formulation corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.